Last reviewed · How we verify
Agent Affecting Integumentary System
At a glance
| Generic name | Agent Affecting Integumentary System |
|---|---|
| Sponsor | City of Hope Medical Center |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Comparing Supplemental Topical Agents for the Treatment of Acute Radiation Dermatitis in Patients With Breast Cancer (PHASE1)
- Efficacy and Safety of Revodiol Calming Cream® in Atopic Dermatitis. (NA)
- Assessment of KM-001 - Safety, Tolerability, and Efficacy in Patients With PPPK1 or PC (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: